Incidence of antiphospholipid antibodies in new patients with non-Hodgkin lymphoma

Author(s):  
Sanda Buruiana ◽  

Non-Hodgkin’s lymphoma (NHL) presents a group of histologically and biologically inhomogeneous B and T cell neoplasms of lymphoid tissue with a completely unidentified etiology. Antiphospholipid antibodies (aPL) are antibodies produced as a result of misinterpretation of platelet membrane phospholipids. It is well known that antiphospholipid antibodies are general risk factors that induce the disorder of the physiological process of hemostasis. Respectively, it is interesting to appreciate the incidence of antiphospholipid antibodies in new non-Hodgkin lymphomas patients depending on age, sex, type of non-Hodgkin’s lymphoma, the peculiarities of the onset of the disease, the degree of disease spread. According to the results of our study, we found a 14.8% incidence of aPL in primary patients with non-Hodgkin’s lymphoma, more frequently in men and people older than 50 years. The positivity of aPL antibodies depended on the immunohistochemical type of malignant lymphoma, the degree of dissemination of the tumor process and independent of the location of the tumor focus (nodal or extranodal) of NHL. The incidence of aPL antibody types was uneven with the obvious predominance of lupus anticoagulant. Th is study allowed the evaluation of the incidence of antiphospholipid antibodies in primary patients with non-Hodgkin’s lymphoma.

1993 ◽  
Vol 70 (04) ◽  
pp. 568-572 ◽  
Author(s):  
Roberto Stasi ◽  
Elisa Stipa ◽  
Mario Masi ◽  
Felicia Oliva ◽  
Alessandro Sciarra ◽  
...  

SummaryThis study was designed to explore the prevalence and clinical significance of elevated antiphospholipid antibodies (APA) titres in patients affected by acute myeloid leukemia (AML) and highgrade non-Hodgkin’s lymphoma (NHL). We also analyzed possible correlations with circulating levels of interleukin-6 (IL-6), tumor necrosis factor-alpha (TNF-alpha), and the soluble form of the receptor for interleukin-2 (sIL-2r). Nineteen patients with de novo AML and 14 patients with newly-diagnosed NHL were investigated. Tests for APA included the measurement of anticardiolipin antibodies (ACA) with a solid-phase immunoassay, and the detection of the lupus-like anticoagulant (LA) activity. Five patients with AML (26.3%) and 5 patients with NHL (35.7%) presented elevated APA at diagnosis, as compared to 3 of 174 persons of the control group (p <0.0001). APA titres became normal in all patients responding to treatment, whereas nonresponders retained elevated levels. In addition, 6 patients (4 with AML and 2 with NHL), who had normal APA at diagnosis and were either refractory to treatment or in relapse, subsequently developed LA and/or ACA positivity. At presentation, the mean levels of IgG- and IgM-ACA in patients were not significantly different from Controls, and concordance between ACA and LA results reached just 30%. With regard to the clinical course, we were not able to detect any statistically significant difference between patients with normal and elevated APA. Pretreatment concentrations of IL-6 and TNF-alpha in AML, and sIL-2r in NHL were found significantly elevated compared to Controls (p = 0.003, p = 0.009 and p = 0.024 respectively). In addition, the levels of these cytokines correlated with IgG-ACA at the different times of laboratory investigations. These results demonstrate that APA may have a role as markers of disease activity and progression in some haematological malignancies.


2021 ◽  
Vol 21 (1) ◽  
Author(s):  
Owrang Eilami ◽  
Max Igor Banks Ferreira Lopes ◽  
Ronaldo Cesar Borges Gryschek ◽  
Kaveh Taghipour

Abstract Background The current literature is scarce as to the outcomes of COVID-19 infection in non-Hodgkin's lymphoma patients and whether immunosuppressive or chemotherapeutic agents can cause worsening of the patients’ condition during COVID-19 infection. Case presentation Our case is a 59-year-old gentleman who presented to the Emergency Department of the Cancer Institute of Hospital das Clínicas da Universidade de São Paulo, São Paulo, Brazil on 10th May 2020 with a worsening dyspnea and chest pain which had started 3 days prior to presentation to the Emergency Department. He had a past history of non-Hodgkin's lymphoma for which he was receiving chemotherapy. Subsequent PCR testing demonstrated that our patient was SARS-CoV-2 positive. Conclusion In this report, we show a patient with non-Hodgkin lymphoma in the middle of chemotherapy, presented a mild clinical course of COVID-19 infection.


2014 ◽  
Vol 3 (2) ◽  
Author(s):  
Dian Rahma Kasir ◽  
Irza Wahid ◽  
Hafni Bachtiar

AbstrakAwal abad ke-2l masyarakat Indonesia mengalami transisi epidemiologi penyakit. Perubahan pola penyakit ini dapat dilihat dari peningkatan insiden penyakit kanker sebagai penyebab kematian di Indonesia dalam 10 tahun terakhir, yaitu dari urutan ke-12 menjadi urutan ke-6. Di Indonesia, limfoma non Hodgkin (LNH) menduduki urutan keenam keganansan yang sering terjadi. Berdasarkan penelitian yang dilakukan oleh Olivia Putri Perdana di bagian patologi anatomi Fakultas Kedokteran Universitas Andalas didapatkan data bahwa pada januari 1997-desember 2001 terdapat 70 (81,39%) penderita limfoma maligna non Hodgkin dari keseluruhan penderita limfoma maligna. Penelitian ini bertujuan untuk mengetahui hubungan kadar laktat dehidrogenase (LDH) dengan stadium pada penderita limfoma maligna non Hodgkin. Penelitian ini adalah penelitian analitik dengan pendekatan cross sectional dengan menggunakan data yang bersumber dari rekam medik pasien. Populasi dari penelitian ini adalah data rekam medik seluruh penderita limfoma maligna non hodgkin yang berobat ke RSUP Dr. M. Djamil Padang yaitu 317 data rekam medik, tetapi yang memenuhi syarat untuk menjadi sampel hanya 40 data. Analisis statistik yang digunakan adalah uji T. Hasil uji statistik menunjukkan adanya hubungan kadar laktat dehidrogenase dengan stadium pada penderita limfoma non Hodgkin (P = 0,001). Diketahui nilai laktat dehidrogenase pada stadium III-IV lebih tinggi daripada nilai laktat dehidrogenase pada stadium I-II.Kata kunci: Laktat dehidrogenase, Limfoma maligna non Hodgkin, Stadium AbstractEarly 21th century, Indonesian society in transition epidemiology of the disease. Changing patterns of disease can be seen from the increased incidence of cancer as a cause of death in Indonesia in the last 10 years, ie from 12th to 6th order. In Indonesia, non-Hodgkin's lymphoma (NHL) ranks sixt frequent in all of cancer. Based on research conducted by Olivia Putri Perdana in anatomic pathology at the Faculty of Medicine, University of Andalas that the data obtained during the January 1997 - December 2001 there were 70 (81.39%) patients with non -Hodgkin's malignant lymphoma of the overall malignant lymphoma patients.This study aims to determine the relationship of levels of lactate dehydrogenase (LDH) with stage of non -Hodgkin's malignant lymphoma patients.This research is a cross sectional analytic approach using data derived from patient medical records. The population is the entire medical record malignant non Hodgkin lymphoma patients who went to DR. M. Djamil Padang hospital, they are 317 medical records, but are eligible to be sampled only 40 data. Statistical analysis used is the T test.Statistical test results show that there is relationship between lactate dehydrogenase levels with stage in non -Hodgkin's lymphoma patients (P = 0.001). Known value of lactate dehydrogenase in stage III - IV is higher than the value of lactate dehidrodenase in stage I - II.Keywords: Lactate dehydrogenase, malignant non-Hodgkin's lymphoma, Stage


1995 ◽  
Vol 81 (2) ◽  
pp. 91-95 ◽  
Author(s):  
Monica Mangiagalli ◽  
Isabella Miccolis ◽  
Pierfranco Maffé ◽  
Enrico Maria Pogliani ◽  
Gianmarco Corneo

Aims and background The study assessed the role and potential benefit of rhG-CSF in reducing the frequency, duration and severity of neutropenia following cytotoxic chemotherapy according to the E-SHAP protocol and, at the same time in improving the response rate. Methods Twenty patients with resistant/relapsed intermediate or high-grade non-Hodgkin's lymphoma were treated with the E-SHAP regimen (etoposide + methyl prednisolone + high dose cytosine arabinoside and cisplatin), and in 15 of them, we administered rhG-CSF between chemotherapeutic courses. Results The 15 patients who received G-CSF after E-SHAP were neutropenic for a short time and experienced no febrile episodes or infective complications. In contrast, in the group (5 patients) who did not receive G-CSF, the WBC nadir was lower and the number of days with a neutrophil count below 1.0 × 109/L was longer, with a greater risk of inferctious complications. Of the 15 patients, only one had a delay in chemotherapy administration, and the RDI was 95% in the 65% of patients who received G-CSF. Of 5 patients treated with chemotherapy alone, 4 had a delay and the RDI was over 95% in only one patient. We obtained a good overall response rate (70%) in the group who received G-CSF. In the historical group of 5 non-Hodgkin lymphoma patients, we observed only 1 partial response and 4 had progression of disease. Conclusions Administration of G-CSF is associated with an acceleration of neutrophil recovery, indicating its potential to reduce the risk of infection. The use of G-CSF permitted us to administer intensive chemotherapy without delay and according to standard dosage, with an improved response rate.


2021 ◽  
Vol 5 (4) ◽  
pp. 134-138
Author(s):  
Glazydia Juwita Rachma ◽  
Ugroseno Yudho Bintoro ◽  
Mia Ratwita Andarsini ◽  
Novira Widajanti

Non-Hodgkin's lymphoma is a major public health problem with over 14.1 million people are diagnosed with it (2012). In the same year there were 8.2 million deaths due to cancer. The purpose of this study was to determine the relationship between clinical manifestations and the degree of malignancy based on histopathological features in patients with Non-Hodgkin's Lymphoma. This study used a retrospective analytical method with a cross-sectional approach using the patient's medical record at RSUD Dr. Soetomo, Surabaya who was diagnosed with Non-Hodgkin Lymphoma from 1st January 2015 to 31st December 2017. In this study, there were 139 samples include those criteria, with a greater number of male samples (62.6%) compared to women (37.4%). This study showed that 49.3% of patients with non- Hodgkin's lymphoma in RSUD Dr. Soetomo with clinical manifestations without symptoms actually experience malignancy with a high degree, this showed that clinical manifestations without symptoms are not always associated with a low level of malignancy. Then, based on the Chi Square test results obtained p-value of 0.289 (>0.05), so there was no significant relationship between clinical manifestations and the degree of malignancy. Keywords: lymphoma; manifestation; histopatological


2009 ◽  
Vol 150 (35) ◽  
pp. 1649-1653
Author(s):  
Balázs Kollár ◽  
Péter Rajnics ◽  
Béla Hunyady ◽  
Erika Zeleznik ◽  
János Jakucs ◽  
...  

A felnőttkori non-Hodgkin-lymphoma előfordulása az elmúlt évtizedekben jelentősen nőtt. A betegcsoport nagyon heterogén, változatos klinikai és morfológiai megjelenéssel. A legjellemzőbb nodalis érintettség mellett gyakoriak az extranodalis formák, amelyek leggyakrabban a gastrointestinalis traktust, a központi idegrendszert és a bőrt érintik. A gastrointestinalis traktus non-Hodgkin-lymphomáinak kezelési stratégiája változott az elmúlt évtizedben, a kemoimmunoterápia háttérbe szorította a korábban jóval gyakrabban végzett sebészeti beavatkozásokat. Módszerek: A szerzők Kaposváron, a Kaposi Mór Oktató Kórházban és Gyulán, a Pándy Kálmán Megyei Kórházban kezelt 48, gastrointestinalis traktust érintő non-Hodgkin-lymphomás betegük adatait mutatják be. A betegek közül 27 nő és 21 férfi, átlagéletkoruk 67,8 év. A leggyakoribb lokalizáció a gyomor ( n = 26), a leggyakoribb szövettani típus diffúz nagy B-sejtes lymphoma (DLBCL) volt. A betegek rizikófaktorait a nemzetközi prognosztikai index (IPI) alapján állapították meg. Negyvenhat beteg kapott kemoimmunoterápiás kezelést, 6 esetben érintett mezős sugárkezelés, 3 esetben Helicobacter pylori -eradikáció, 4 betegnél gyomorreszekció történt. Eredmények: Az összes beteg 68%-ában sikerült komplett, 13%-ában parciális remissziót elérni, 19% nonreszponder volt. A nemzetközi prognosztikai index alapján a betegek többsége az alacsony, illetve magas intermedier rizikócsoportba tartozott (IPI-átlag: 2,68). A tápcsatorna felső szakaszát érintő lymphomás betegek prognózisa volt a legjobb (IPI: 2,0), ugyanakkor a gyomorlymphomás betegeknél volt a legmagasabb a komplett remisszió aránya (73%). Következtetés: Kemoimmunoterápiával a betegek gyógyulási esélyei javultak az elmúlt évtizedben, a gastrointestinalis traktust érintő non-Hodgkin-lymphomák jelentős hányada meggyógyítható. Az IPI a legelfogadottabb mutató a non-Hodgkin-lymphoma prognózisának megítélésére. A komplett remisszióba jutott betegek prognosztikai indexe volt a legalacsonyabb, de az IPI-n kívül egyéb tényezők is befolyásolhatják a kezelésre adott választ.


2006 ◽  
Vol 76 (5) ◽  
pp. 384-391 ◽  
Author(s):  
Osnat Bairey ◽  
Dorit Blickstein ◽  
Yehudit Monselise ◽  
Judith Lahav ◽  
Pinhas Stark ◽  
...  

2020 ◽  
Vol 40 (05) ◽  
pp. 662-670
Author(s):  
Rimesh Pal ◽  
Subhash Varma ◽  
Jasmina Ahluwalia ◽  
Gaurav Prakash

Abstract Background Antiphospholipid antibodies (APAs) are found quite frequently in patients with non-Hodgkin’s lymphoma (NHL). However, the clinical significance of these antibodies is largely unknown. This study aims to delineate the clinical and prognostic role of APAs in NHL patients. Patients and Methods  Consecutive patients of NHL were screened for lupus anticoagulant (LA), IgG/IgM anticardiolipin antibody, and IgG/IgM anti-β2-glycoprotein I at the time of diagnosis. Baseline investigations, staging, and treatment were done as per institutional protocol. Patients were followed up until the last known outpatient visit or death. All were screened at each visit for any thromboembolic event. The association of APA status with baseline NHL characteristics and treatment response was evaluated by univariate analysis. Kaplan–Meier survival analysis was used to compare the final outcome in patients with or without APAs. Patients who were initially APA positive were retested for the corresponding antibody at the end of chemotherapy. Results Twenty-four out of 105 patients (22.8%) were APA positive at diagnosis. The presence of APA was not significantly associated with NHL stage, histology, International Prognostic Index score, activated partial thromboplastin time, or treatment response. The median duration of follow-up was 15 months. Only four patients developed venous thrombosis; none was APA positive. There was no statistically significant difference in overall survival between the two groups (p = 0.471). Patients, who were APA positive initially, tested negative at the end of treatment, irrespective of treatment response. Conclusion APAs are encountered more frequently in NHL patients than in the general population. However, APAs do not correlate with disease severity, thrombosis risk, treatment outcome, or overall survival.


Blood ◽  
2005 ◽  
Vol 106 (11) ◽  
pp. 4689-4689
Author(s):  
Sonja G. Genadieva-Stavrik ◽  
Ljube G. Ivkovsi ◽  
Gorgi D. Zografski ◽  
Borce A. Georgievski ◽  
Zlate R. Stojanoski ◽  
...  

Abstract There are two subgroups of the untreated lymphomas according to the outcome of the disease: indolent and aggressive. Unlike the indolent lymphoma, aggressive lymphomas are fatal in several weeks or months if untreated. However, the therapy available nowadays makes this group of patients with aggressive Non-Hodgkin’s lymphoma curable. Autologous stem cell transplantation used as first-line therapy can improve overall survival in selected group of patients with aggressive Non-Hodgkin lymphoma. To make the right and optimal therapeutic approach we need to stratify those patients in subgroups of patients with "high" and "low" risk, which was achieved with this study. This study comprises 211 patients with histopathology diagnosis of aggressive Non-Hodgkin’s lymphoma treated at the Department of Hematology in the period 1989–2002, which gave us the observation period of 6 to 183 months. There were 88 male patients, median age 53 years and 60 female, median age 52 years. Most of the patients were in the advanced clinical stage at the disease on the initial presentation of the disease, 24% of the patients in the third stage and 43% in the fourth stage. Bone marrow infiltration was found in 29%. Bcl-2 positively was confirmed in 26 cases by imunohistochemistry and there was proliferative index Ki-67 above 60% in 32 patients. Imunophenotipisation suggested that 80% of the cases are B-cell lymphoma. The patients were treated with antracicilin included regiments, most of them being CHOP regiment. After initial chemotherapy complete remission was achieved in 60%, partial response in 4% and there was no response in 32% with early deaths in 4%. At the end of the study 32% of the patients were alive and well, 32% were deceased and the reminder had unknown status. There was relapse of the disease in 50 patients with previous complete remission. According to the univariante analysis the following parameters had significantly influence the overall survival in the patients with aggressive Non-Hodgkin’s lymphoma: initial anemia, initial LDH, the stage of the disease, ECOG score, bone marrow infiltration, number of sites of extranodal infiltration, lymphoma subgroup according to various classification systems, morphology of the lymphoma cell, imunophenotype profile, percent of Ki-67 positively, bcl-2 positively, time to complete remission. The multiply progression analysis produce mathematical model through which we can anticipate the expected survival in each patients individually based on the statistically most influential prognostic markers, those achieving stratification of the patients in risk groups. In our study 32% of the patients with "high" risk are alive and "low risk patients have 70% 5-years overall survival. With the use of this prognostic model for aggressive Non-Hodgkin’s lymphoma we achieved risk based stratification of the patients even in the fourth stage of the disease with statistical significance. This prognostic model for aggressive Non-Hodgkin’s lymphoma enables the clinical hematologist to create the optimal individual therapeutic approach for each patient with aggressive Non-Hodgkin’s lymphoma. The patients with "high" risk are group of patients where beside the standard chemotherapy, use of aggressive chemotherapy and haematopoetic stem cell transplantation as well as the new therapeutic approaches would improve therapeutic results and overall survival.


Sign in / Sign up

Export Citation Format

Share Document